Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €7.32 EUR
Change Today -0.085 / -1.15%
Volume 0.0
ADA On Other Exchanges
As of 3:20 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ADA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - €20.19
52 Week Low
08/8/14 - €5.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

achillion pharmaceuticals (ADA) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ADA) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which completed Phase II clinical trial. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize the company’s hepatitis C virus assets. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

67 Employees
Last Reported Date: 03/5/15
Founded in 1998

achillion pharmaceuticals (ADA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $484.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $347.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $457.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.4K
Compensation as of Fiscal Year 2014.

achillion pharmaceuticals (ADA) Key Developments

Achillion Pharmaceuticals, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015

Achillion Pharmaceuticals, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015 . Venue: Boston Harbor Hotel, 70 Rowes Wharf, Boston, MA 02110, United States. Speakers: Glenn Schulman, Senior Director, IR, Mary Kay Fenton, Chief Financial Officer, Executive Vice President and Secretary, Milind S. Deshpande, Chief Executive Officer, President and Director.

Achillion Pharmaceuticals, Inc. Announces Resignation of Dennis Liotta as Class I Director

Dennis Liotta, a Class I director of Achillion Pharmaceuticals, Inc. resigned from the company’s Board of Directors.

Achillion Pharmaceuticals Inc. Enters into Worldwide License and Collaboration Arrangement with Janssen Pharmaceuticals

Achillion Pharmaceuticals Inc. (ACHN) has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals Inc., to develop and commercialize one or more of Achillion's lead hepatitis C virus assets which include ACH-3102, ACH-3422, and Sovaprevir. The collaboration focuses on the development of a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of hepatitis C virus, or HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in phase 2 clinical studies in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Achillion is eligible to receive about $1.1 billion in potential development, regulatory and sales milestone payments under the collaboration. Additionally, Johnson & Johnson Innovation - JJDC, Inc. will invest $225 million in Achillion and, in return, receive about 18.4 million newly issued, unregistered shares of Achillion at a price of $12.25 per share. Derma Sciences Inc. (DSCI) is aiming to complete enrollment in its phase III program with Aclerastide in subjects with diabetic foot ulcers by the end of June 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADA:GR €7.32 EUR -0.085

ADA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at